<?xml version="1.0" encoding="ISO-8859-1"?><rss version="2.0"><channel><title>medsurfnews.com</title><link>http://mn.medsurfnews.com</link><description>Le ultime risorse da Medsurfnews.com</description><language>it</language><pubDate></pubDate><copyright>Healthwaregroup.com</copyright><webmaster>francesco.raimondo@healthware.it</webmaster><image><title>Medsurfnews Rss</title><url>http://mn.medsurfnews.com/images/logo.jpg</url><link>http://mn.medsurfnews.com</link></image>

	
	
<item>

<title>Spironolactone and trimethoprim: a dangerous association</title>
<link>http://mn.medsurfnews.com/contents/it/7211/display/spironolactone-and-trimethoprim-a-dangerous-association.aspx</link>
<pubDate>Mon, 16 Apr 2012 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[Prolonged use of potassium-sparing diuretics such as spironolactone may induce the onset of hyperkalemia, especially when spironolactone is used in combination with other drugs which themselves can cause an increase in potassium, such as ACE inhibitors. One drug which has this feature is [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/7211_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/7211_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Quadruple therapy against Helicobacter </title>
<link>http://mn.medsurfnews.com/contents/it/7056/display/quadruple-therapy-against-helicobacter-.aspx</link>
<pubDate>Mon, 13 Feb 2012 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[Treatment for the eradication of Helicobacter Pylori (HP) involves the contemporary administration of omeprazole, clarithromycin and amoxicillin (OCA), although this scheme is often invalidated by the increasing resistance to the macrolide. This fact has promoted the use of a quadruple therapy [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/7056_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/7056_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Phentermine and Topiramate to Lose Weight</title>
<link>http://mn.medsurfnews.com/contents/it/6786/display/phentermine-and-topiramate-to-lose-weight.aspx</link>
<pubDate>Mon, 17 Oct 2011 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[Trying to help pharmacologically subjects wanting to lose weight, many drugs have been marketed, but quite all of them have been abandoned because of their side effects. A new attempt has been now performed in the USA randomizing 2,487 obese people (BMI 27-45 kg/m2, with two or more comorbities) to [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6786_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6786_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Rosiglitazone and Pioglitazone</title>
<link>http://mn.medsurfnews.com/contents/it/6745/display/rosiglitazone-and-pioglitazone.aspx</link>
<pubDate>Mon, 26 Sep 2011 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[Two of the available thiazolidinodiones for the therapy of type 2 diabetes, pioglitazone and rosiglitazone, this second one has been gradually abandoned because of an increased risk of cardiovascular ischemic events, even if both cause an increased frequency of heart failures. With a meta-analysis [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6745_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6745_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Tioropium or Salmeterol in COPD?</title>
<link>http://mn.medsurfnews.com/contents/it/6740/display/tioropium-or-salmeterol-in-copd.aspx</link>
<pubDate>Mon, 19 Sep 2011 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[In the first line, in the treatment of COPD and in its exacerbations, there are inhaled anticholinergics and long-action beta-agonists, but which of these two drug classes is more effective? In order to answer this question, an international, double-blinded, randomized study has been performed, [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6740_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6740_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Exenatide and Insulin</title>
<link>http://mn.medsurfnews.com/contents/it/6660/display/exenatide-and-insulin.aspx</link>
<pubDate>Mon, 29 Aug 2011 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[The mechanism with which exenatide acts is well known: it increases insulin secretion, it decreases glucagone secretion and it slows gastric emptying down: its use is approved in association with any oral glucose-lowering drug but not with insulin. In this study, sponsored by pharmaceutical [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6660_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6660_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>DRESS: Drug Hypersensitivity</title>
<link>http://mn.medsurfnews.com/contents/it/6641/display/dress-drug-hypersensitivity.aspx</link>
<pubDate>Mon, 25 Jul 2011 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[The outburst of systemic reactions associated with eosinophilia, a consequence of the assumption of a specific drug in the body which is known under the name of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) and it represents one of the worst inconvenient events linked to [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6641_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6641_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Prophylaxis of Venous Thromboembolism</title>
<link>http://mn.medsurfnews.com/contents/it/6555/display/prophylaxis-of-venous-thromboembolism.aspx</link>
<pubDate>Mon, 27 Jun 2011 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[The risk of thromboembolic perioperative complications in patients undergoing hip prostheses is very high, so the prevention protocol implies the use of low-molecular-weight heparin or of vitamin K antagonists, like warfarin. Heparin requires however a subcutaneous injection, while warfarin needs [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6555_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6555_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Rivaroxaban in DVTs</title>
<link>http://mn.medsurfnews.com/contents/it/6549/display/rivaroxaban-in-dvts.aspx</link>
<pubDate>Mon, 20 Jun 2011 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[In situations requiring a situation of reduced coagulability, like, for example, in deep venous thromboses (DVTs), a new series of drugs are gradually occupying important roles. Among these ones, the specific coagulation factor inhibitors, like rivaroxaban, which, through oral administration, [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6549_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6549_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	
<item>

<title>Dabigatran or Warfarin in Atrial Fibrillation?</title>
<link>http://mn.medsurfnews.com/contents/it/6550/display/dabigatran-or-warfarin-in-atrial-fibrillation.aspx</link>
<pubDate>Mon, 20 Jun 2011 12:00:00 +0200</pubDate>
<category>Farmacologia</category>
<description><![CDATA[Warfarin properties are well known: preventive efficacy in patients with AF and therapeutical efficacy in patients with pulmonary embolism and/or venous thrombosis, not considering its use in conditions of embolic risk or in patients with anticardiolipin antibodies syndrome. The use of warfarin, [...]]]></description>

<enclosure url="http://mn.medsurfnews.com/mp3/6550_fast.mp3" type="audio/mpeg" length=""/>


<enclosure url="http://mn.medsurfnews.com/mp3/6550_slow.mp3" type="audio/mpeg" length=""/>
		
</item>	
	
	
	
	
	</channel></rss>
	



